Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma
For inoperable esophageal adenocarcinoma (EAC), identifying patients likely to benefit from recently approved immunochemotherapy (ICI+CTX) treatments remains a key challenge. We address this using a uniquely designed window-of-opportunity trial (LUD2015-005), in which 35 inoperable EAC patients rece...
Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Άλλοι συγγραφείς: | |
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Cell Press
2023
|